Similarly, a high pre-treatment sPD-L1 levels were associated with advanced stage in a cohort consisted of 128 patients with non-small cell lung cancer (n = 50), melanoma (n = 31), small cell lung cancer (n = 14), urothelial carcinoma (n = 13), and other cancers (n = 20). This evidence concerns the gene SPDL1 and melanoma.